Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Completes $3.3 Billion Privatization

publication date: Dec 11, 2015
WuXi PharmaTech, China's largest CRO, has completed its $3.3 billion privatization and de-listed its shares from the New York Stock Exchange as of December 10. Ally Bridge Group was the initial named investor in the deal. It was joined by Boyu Capital, units of Ping An Insurance (Group) Co. of China, Singapore's Temasek Holdings and Hillhouse Capital along with Dr. Ge Li, WuXi PharmaTech's Chairman and CEO and other management executives. In 2006, just before WuXi IPO'd in New York, it had revenues of $70 million. In 2015, its revenues will be at least 12 times that. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital